Versant Ventures

Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.

Pep2Tango Therapeutics is a biotechnology company that offers superior unimolecular multi-receptor drugs for obesity and related disorders.

858 Therapeutics is a biotechnology company dedicated to discovering small molecule therapeutics aimed at treating cancers, particularly those resistant to existing therapies. The company employs innovative strategies centered on synthetic lethality, innate immunity, and RNA modulation to develop its drug pipeline. Its lead program focuses on a PARG inhibitor, which is currently undergoing early clinical development. By leveraging its platform to evaluate the effects of RNA modifying proteins on disease biology, 858 Therapeutics aims to generate effective treatments for challenging oncological targets.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based medicines specifically for kidney diseases. The company utilizes its expertise in molecular and cellular biology, chemistry, and analytical capabilities to identify target opportunities within different patient subsets affected by kidney conditions. By refining methods for delivering RNA medicines to specific cell types, Borealis Biosciences aims to tackle significant unmet medical needs in the treatment of kidney diseases.

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

SixPeaks Bio focuses on developing innovative therapies aimed at promoting healthy weight loss for individuals struggling with obesity. The company is working on a pipeline of medicines that utilize dual-specific antibodies to target activin type IIA and B receptors. This approach aims to help patients achieve weight loss while preserving skeletal muscle mass, addressing a common concern associated with traditional weight-loss methods that often lead to muscle loss alongside fat reduction. Through its research and development efforts, SixPeaks Bio seeks to provide effective solutions for sustainable weight management and improved health outcomes.

FireFly Bio focuses on developing Degrader Antibody Conjugates (DACs), a novel approach that merges the benefits of antibody-drug conjugates with selective protein degraders. This proprietary healthcare platform is designed to enhance cancer treatment by ensuring the precise delivery of therapeutic agents to targeted tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create more effective and targeted medicines that improve patient outcomes in the fight against cancer.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.

Nexo Therapeutics is a biotechnology company focused on developing small-molecule therapies for cancer patients who have few effective treatment options. The company utilizes a specialized platform that integrates covalent ligand discovery with chemical biology to create innovative oncology drugs aimed at challenging targets that have been difficult to address in the past. By advancing its pipeline of novel therapies, Nexo Therapeutics seeks to provide new avenues for treatment, ultimately enhancing the care available to individuals battling cancer and other related diseases.

Kate Therapeutics is a biotechnology company dedicated to developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases. The company employs advanced technology platforms to enhance tissue-specific delivery and gene regulation, overcoming significant challenges associated with current gene therapies. By utilizing innovative capsids, Kate Therapeutics achieves superior muscle transduction and effectively de-targets the liver, allowing for more efficient tissue transduction at lower viral doses. This approach addresses key limitations in muscle gene delivery, aiming to improve treatment outcomes for patients with muscle and heart conditions.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Santa Ana Bio is a biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases. By utilizing advanced technologies such as deep cell profiling, single-cell genomics, and multi-omics platforms, the company designs targeted biologics that aim to provide effective and personalized treatment options. Through its innovative approach, Santa Ana Bio seeks to enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.

Launchpad Therapeutics operates as an antibody-focused precision oncology company.

Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders. The technology platform developed by Cimeio is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. The SCIP platform could allow more patients facing debilitating and fatal diseases to receive a life-saving HSC transplant. Its mission is to significantly improve the eligibility and outcomes of hematopoietic stem cell transplants and adoptive cell therapy.

Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.

SanReno Therapeutics specializes in the development, manufacturing, and commercialization of therapies for kidney diseases in several regions including the People's Republic of China, Hong Kong, Macau, Taiwan, and Singapore. Established through a joint venture involving Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, the company is dedicated to researching and producing innovative biotech solutions aimed at improving the quality of life for patients suffering from kidney-related conditions.

ViaLase is a medical technology company based in Corona Del Mar, California, that specializes in developing an innovative image-guided femtosecond laser surgical system for treating open-angle glaucoma. Founded in 2019, the company utilizes micron-resolution optical coherence tomography (OCT) to guide its laser technology in creating precise, micron-sized drainage channels through the trabecular meshwork. This approach connects the anterior chamber to Schlemm's canal without the need for surgical incisions or penetration of the eye, thereby offering a non-invasive treatment option for glaucoma management. By enhancing the efficiency of glaucoma procedures, ViaLase aims to improve patient outcomes in this challenging area of ophthalmic care.

858 Therapeutics is a biotechnology company dedicated to discovering small molecule therapeutics aimed at treating cancers, particularly those resistant to existing therapies. The company employs innovative strategies centered on synthetic lethality, innate immunity, and RNA modulation to develop its drug pipeline. Its lead program focuses on a PARG inhibitor, which is currently undergoing early clinical development. By leveraging its platform to evaluate the effects of RNA modifying proteins on disease biology, 858 Therapeutics aims to generate effective treatments for challenging oncological targets.

Stablix Therapeutics is a biotechnology company specializing in Targeted Protein Stabilization (TPS). The company has developed a platform that produces heterobifunctional small molecules, known as RESTORACS, which selectively recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins. This process enhances the stability and activity of these proteins. Stablix focuses on utilizing its innovative technology to create therapeutic programs aimed at treating rare diseases, cancer, and immunological disorders. By restoring protein function, Stablix aims to provide more effective treatment options for complex medical conditions.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Century Therapeutics is a biotechnology company focused on developing advanced cell therapies using induced pluripotent stem cells (iPSCs) to treat various cancers, including hematologic and solid tumors. Founded in 2018 and based in Philadelphia, Pennsylvania, the company utilizes a unique allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, and robust manufacturing capabilities. This innovative approach allows for the generation of modified immune effector cells, such as natural killer (NK) and T cells, designed to meet significant unmet medical needs. By employing techniques like CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to enhance cell product performance and minimize rejection by the host immune system, thereby improving the efficacy of cancer treatments.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in developing innovative treatments for severe rare diseases with significant unmet medical needs. Its primary product candidate, Apraglutide, is a long-acting synthetic analog of glucagon-like peptide-2 (GLP-2) designed to enhance the intestine's ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support. VectivBio aims to deliver transformational therapies that significantly improve the lives of patients and their families, rather than offering only incremental benefits over existing treatments.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Chinook Therapeutics is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in developing precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently undergoing Phase III trials for IgA nephropathy and other glomerular diseases. Additionally, Chinook is evaluating BION-1301, an anti-APRIL monoclonal antibody, in a Phase Ib trial for IgA nephropathy. The company is also advancing CHK-336, a preclinical candidate targeting an undisclosed ultra-orphan kidney disease, along with research initiatives focused on other rare and severe chronic kidney conditions, including polycystic kidney disease. Chinook Therapeutics aims to address significant unmet medical needs in the field of nephrology through its innovative product pipeline.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in developing innovative treatments for severe rare diseases with significant unmet medical needs. Its primary product candidate, Apraglutide, is a long-acting synthetic analog of glucagon-like peptide-2 (GLP-2) designed to enhance the intestine's ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support. VectivBio aims to deliver transformational therapies that significantly improve the lives of patients and their families, rather than offering only incremental benefits over existing treatments.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

Chinook Therapeutics is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in developing precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently undergoing Phase III trials for IgA nephropathy and other glomerular diseases. Additionally, Chinook is evaluating BION-1301, an anti-APRIL monoclonal antibody, in a Phase Ib trial for IgA nephropathy. The company is also advancing CHK-336, a preclinical candidate targeting an undisclosed ultra-orphan kidney disease, along with research initiatives focused on other rare and severe chronic kidney conditions, including polycystic kidney disease. Chinook Therapeutics aims to address significant unmet medical needs in the field of nephrology through its innovative product pipeline.

Century Therapeutics is a biotechnology company focused on developing advanced cell therapies using induced pluripotent stem cells (iPSCs) to treat various cancers, including hematologic and solid tumors. Founded in 2018 and based in Philadelphia, Pennsylvania, the company utilizes a unique allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, and robust manufacturing capabilities. This innovative approach allows for the generation of modified immune effector cells, such as natural killer (NK) and T cells, designed to meet significant unmet medical needs. By employing techniques like CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to enhance cell product performance and minimize rejection by the host immune system, thereby improving the efficacy of cancer treatments.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.

Inari Medical, Inc. is a commercial-stage medical device company headquartered in Irvine, California, that specializes in developing innovative products for patients with venous diseases. Founded in 2011, the company focuses on treating venous thromboembolism through its advanced catheter-based mechanical thrombectomy devices. The ClotTriever system is designed for the safe and effective removal of large blood clots from peripheral blood vessels, specifically targeting deep vein thrombosis. The FlowTriever system addresses pulmonary embolism by removing clots from the pulmonary arteries. Both devices are FDA-cleared and aim to improve the quality of life for patients by eliminating the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States, while also engaging in international markets.

Quentis Therapeutics, Inc. is a biotechnology company based in New York, founded in 2016. The company specializes in developing immunotherapies that target endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By addressing ER stress, Quentis aims to enhance the immune system's capacity to combat cancer, providing patients with innovative treatment options. Its therapeutic approach focuses on awakening anti-tumor immunity, thereby potentially improving outcomes for individuals facing various forms of cancer.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.

Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Kyras Therapeutics Inc. is a biotechnology company based in New York, specializing in the development of drugs aimed at treating incurable cancers and developmental disorders. Founded in 2015, the company focuses on addressing conditions linked to mutations in RAS genes, which are responsible for a significant percentage of various cancers, including pancreatic, colorectal, and lung cancers. By targeting these mutations, Kyras Therapeutics aims to provide effective treatments that can potentially cure patients suffering from these challenging health issues.

Inception IBD is focused on translating academic discoveries in the field of IBD

Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds. PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancers and genetic diseases. The company lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology. PIQUR Therapeutics was founded in 2011 and is based in Basel, Switzerland.

Inari Medical, Inc. is a commercial-stage medical device company headquartered in Irvine, California, that specializes in developing innovative products for patients with venous diseases. Founded in 2011, the company focuses on treating venous thromboembolism through its advanced catheter-based mechanical thrombectomy devices. The ClotTriever system is designed for the safe and effective removal of large blood clots from peripheral blood vessels, specifically targeting deep vein thrombosis. The FlowTriever system addresses pulmonary embolism by removing clots from the pulmonary arteries. Both devices are FDA-cleared and aim to improve the quality of life for patients by eliminating the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States, while also engaging in international markets.

Zyga Technology, Inc. is a medical device company focused on developing and commercializing minimally invasive products for underserved conditions of the lumbar spine. The company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion, addressing issues such as joint disruptions and degenerative sacroiliitis. Additionally, Zyga is working on the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology has assembled a skilled team with extensive experience in the spine industry. As of late 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Ceterix Orthopaedics, Inc. is a medical technology company focused on developing innovative surgical tools for arthroscopic procedures. Based in Fremont, California, the company offers the Ceterix NovoStitch® Plus Meniscal Repair System, designed to repair various complex meniscal tears, including horizontal, radial, and root tears. Additionally, Ceterix provides the Novocut Suture Manager, a device that facilitates suture management during surgeries. The company's technology allows orthopedic surgeons to non-invasively create intricate suture patterns in tight joint compartments while safeguarding surrounding structures such as nerves and cartilage. Founded in 2010 by Dr. Justin Saliman, an orthopedic surgeon specializing in sports medicine, Ceterix aims to enhance the outcomes of arthroscopic procedures, addressing issues that often lead to untreated tears or the more invasive meniscectomy. As of January 2019, Ceterix operates as a subsidiary of Smith & Nephew plc.

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

RedBrick Health, based in Minneapolis and established in 2006, focuses on addressing the rising costs of healthcare by offering innovative solutions that promote healthier behaviors among consumers. The company provides technology-enabled enterprise services that facilitate informed healthcare decisions through a combination of behavior-based health financing, personalized programs, and independent advocacy. By leveraging advanced behavior design and insights from data analytics, RedBrick Health aims to enhance consumer engagement and improve the effectiveness of population health and well-being initiatives for employers, health plans, health systems, and accountable care organizations. Through these efforts, RedBrick Health seeks to create better consumer health outcomes and support its clients in managing healthcare costs more effectively.

ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds. PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancers and genetic diseases. The company lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology. PIQUR Therapeutics was founded in 2011 and is based in Basel, Switzerland.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

Inception Sciences, Inc. is a drug discovery company established in 2011, located in San Diego, California, with additional research facilities in Vancouver and Saint Laurent, Canada. The company specializes in developing small molecule therapies aimed at addressing diseases and disorders that have significant unmet medical needs. By collaborating with academic experts, Inception Sciences translates biological insights into innovative and targeted drug candidates. The team boasts a strong history in drug discovery, having contributed to the development of clinical-stage compounds for conditions such as fibrosis, asthma, and chronic obstructive pulmonary disease (COPD) while previously working with notable pharmaceutical firms.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

Inari Medical, Inc. is a commercial-stage medical device company headquartered in Irvine, California, that specializes in developing innovative products for patients with venous diseases. Founded in 2011, the company focuses on treating venous thromboembolism through its advanced catheter-based mechanical thrombectomy devices. The ClotTriever system is designed for the safe and effective removal of large blood clots from peripheral blood vessels, specifically targeting deep vein thrombosis. The FlowTriever system addresses pulmonary embolism by removing clots from the pulmonary arteries. Both devices are FDA-cleared and aim to improve the quality of life for patients by eliminating the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States, while also engaging in international markets.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in improving patient care through advanced genomic testing. The company offers a range of diagnostic products, including the Afirma Genomic Sequencing Classifier for thyroid cancer, the Percepta Genomic Sequencing Classifier for lung cancer, the Envisia Genomic Classifier for idiopathic pulmonary fibrosis, and the Prosigna Breast Cancer Prognostic Gene Signature Assay. These tests help identify benign conditions, differentiate diseases, and assess cancer recurrence risk, thereby reducing the need for invasive procedures and expediting treatment decisions. Veracyte collaborates with various organizations, including Johnson & Johnson, to enhance the development and commercialization of innovative diagnostic tests. With a commitment to leveraging genomic science and technology, Veracyte aims to deliver effective solutions for patients and healthcare providers globally.

ForSight Labs is focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients. Our environment is creative and collaborative; a place where entrepreneurs and investors work together to drive innovative technologies through concept, development, and ultimately commercialization in high-impact eye care companies (ForSight VISION companies). Each day millions of people rely on their vision and suffer when it is lost. There are few disabilities as impactful to quality of life as the loss of vision. The number of people with impaired vision in the US, including blindness, is expected to more than double over the next three decades. Recent estimates of the cost of vision loss in the US exceed $50 billion dollars annually. ForSight Labs brings together highly motivated and capable team members, clinicians and investors focused on starting and sustaining efforts to deliver innovative solutions to the ophthalmic community and the patients it serves.

RedBrick Health, based in Minneapolis and established in 2006, focuses on addressing the rising costs of healthcare by offering innovative solutions that promote healthier behaviors among consumers. The company provides technology-enabled enterprise services that facilitate informed healthcare decisions through a combination of behavior-based health financing, personalized programs, and independent advocacy. By leveraging advanced behavior design and insights from data analytics, RedBrick Health aims to enhance consumer engagement and improve the effectiveness of population health and well-being initiatives for employers, health plans, health systems, and accountable care organizations. Through these efforts, RedBrick Health seeks to create better consumer health outcomes and support its clients in managing healthcare costs more effectively.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Minerva Surgical Inc. is a medical technology company based in Redwood City, California, specializing in women's healthcare. Founded in 2008, the company develops, manufactures, and commercializes minimally invasive solutions aimed at addressing the unique uterine health needs of women. Its flagship product, The Minerva Endometrial Ablation System, provides a treatment option for abnormal uterine bleeding, a common issue among women. Minerva Surgical offers a range of alternatives to hysterectomy, designed to tackle the leading causes of abnormal uterine bleeding while preserving the uterus and minimizing the drawbacks associated with traditional treatment methods. The company's solutions are suitable for various medical settings, reflecting its commitment to improving women's health outcomes.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company offers ZILRETTA, an intra-articular injection designed to manage knee pain associated with osteoarthritis in the United States. Additionally, Flexion is developing FX201, a gene therapy aimed at stimulating the production of an anti-inflammatory protein to provide pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Founded in 2007, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates through clinical proof of concept and beyond, thereby enhancing their partners' portfolios while sharing expertise and risk.

Cotera, Inc. specializes in the design and development of orthopedic implants aimed at treating knee osteoarthritis. Founded in 2011 and located in Menlo Park, California, the company has introduced innovative devices, including the Latella device, which is surgically attached to the femur to alleviate medial knee pain associated with osteoarthritis. This implant not only provides immediate relief but is also designed for easy removal, preserving future treatment options for patients. Cotera's focus is on improving the quality of life for individuals suffering from joint pain through advanced orthopedic solutions.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs. ForSight VISION5 is developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy. The company is currently in its second Phase 2 clinical study for its lead product, the Helios insert.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such as fibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia.

Zyga Technology, Inc. is a medical device company focused on developing and commercializing minimally invasive products for underserved conditions of the lumbar spine. The company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion, addressing issues such as joint disruptions and degenerative sacroiliitis. Additionally, Zyga is working on the Glyder Facet Restoration System, an investigational device aimed at treating chronic facetogenic pain. Founded in 2008 and based in Minnetonka, Minnesota, Zyga Technology has assembled a skilled team with extensive experience in the spine industry. As of late 2017, Zyga operates as a subsidiary of RTI Surgical, Inc.

Five Prime Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of innovative protein therapeutics. The company is advancing several product candidates, including Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b (FGFR2b), currently in Phase 3 clinical trials for gastric and gastroesophageal junction cancer. Other candidates include FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for various cancers, and FPT155, a soluble CD80 fusion protein enhancing T cell co-stimulation, also in Phase 1a/1b trials. Additionally, Cabiralizumab, which inhibits colony stimulating factor-1 receptor, is undergoing Phase Ia/Ib trials in combination with other therapies. The company employs its ProScreen Engine to systematically screen all relevant human proteins, enabling rapid and high-quality therapeutic development. Five Prime Therapeutics has established collaborations and license agreements with several pharmaceutical companies, enhancing its research and development capabilities. Founded in 2001, the company continues to focus on advancing novel therapies for challenging cancer indications.

Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

RedBrick Health, based in Minneapolis and established in 2006, focuses on addressing the rising costs of healthcare by offering innovative solutions that promote healthier behaviors among consumers. The company provides technology-enabled enterprise services that facilitate informed healthcare decisions through a combination of behavior-based health financing, personalized programs, and independent advocacy. By leveraging advanced behavior design and insights from data analytics, RedBrick Health aims to enhance consumer engagement and improve the effectiveness of population health and well-being initiatives for employers, health plans, health systems, and accountable care organizations. Through these efforts, RedBrick Health seeks to create better consumer health outcomes and support its clients in managing healthcare costs more effectively.

Intuity Medical, Inc. is a company focused on developing innovative blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, Intuity Medical is known for its POGO Automatic Blood Glucose Monitoring System, which is the first FDA-cleared automatic device that integrates lancing, blood collection, and analysis into a single 10-test cartridge. This system offers a convenient and discreet solution for individuals who need to regularly monitor their blood glucose levels, making it easier for millions of patients to manage their diabetes effectively. The company was previously named Rosedale Medical, Inc. before rebranding in June 2007.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

HALSCION, INC. develops devices to improve wound healing and the resulting scar outcomes. The company offers single-use hydrogel scaffolds that are applied during surgery to the dermal-subdermal interface of wound by injection. Its products include biocompatible materials that provide a structural framework upon, which wound healing cells, such as fibroblasts migrate into the wound and organize. The company was incorporated in 2005 and is based in Suwanee, Georgia.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Synosia Therapeutics is a privately-owned company focused on developing and commercializing products to address unmet medical needs in the fields of psychiatry and neurology. The company has a pipeline that includes six clinical-stage compounds, which have been acquired through partnerships with major pharmaceutical companies. Two of these compounds are existing marketed drugs that are undergoing testing for new indications, aiming to expand their applications to treat neurological and psychiatric conditions such as anxiety and Parkinson's disease. In addition to its product development efforts, Synosia Therapeutics also offers clinical development programs and research services.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.